Theranos Won’t Discuss Disruptive Lab Technology

CEO SUMMARY: In a partnership with Walgreens pharmacies, Theranos Inc. announced that it will run clinical lab tests on “micro-samples” and collect these blood samples without venipuncture. Even as Theranos touts the patient-friendly benefits of its proprietary diagnostic technology, it has provided no information about the science that supports this testing and the clinical validations …

Theranos Won’t Discuss Disruptive Lab Technology Read More »

To access this post, you must purchase The Dark Report.

Theranos Won’t Discuss Disruptive Lab Technology

Despite claims it can do clinical lab testing priced at 50% of Medicare, science is unknown

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month